It is all about cash at hand, and/or possibility of cash coming in before it dips to alarming levels.
Pre-clinical data however good does not amuse the market that expects more from a company at this stage especially when the company calls itself a late stage biotech. Does ADXS have any breakthrough news or data to report that will kick start the ascent of pps to double digits ?
Take a look at the 12 trials that ADXS has on the clinical trials website and see how many trials are : active and recruiting, not recruiting, suspended, terminated etc. and how far the company is from knocking the FDA's door. Even EMA approval decision seems light years away considering the cash at hand needed to survive to look forward to that event. The company burns 15 million a Qtr. and we know EMA decision is still at least 2 or even 3 Qtrs. away, depending on one's view.
Going by the discussion on this board, NEO dosing may bring in anywhere from 20 million (high end) to even 5 million (low end). Consolation that something is better than nothing at this moment in time. The talk of 500 million in licensing deals is nice to hear, but ADXS has to jump over all the high hurdles in a timely manner, over the next few years without tripping - a big deal for ADXS that it has never done it all these years.
June 7th, we will know about cash position as of April 30, 2018; all other discussion about what a great pipeline the company has, the potential to cure various cancers, etc. is moot and has been repeated year after year - nothing new about it.
How many ADXS Employees does it take to change a light bulb?
